Recent Advances in Novel Cell and Gene Therapies for the Treatment of Immune Diseases
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: 20 April 2026 | Viewed by 1146
Special Issue Editor
2. HLA Lab, CancerCare Manitoba, Winnipeg, MB R3A 1R9, Canada
3. Department of Immunology, University of Manitoba, Winnipeg, MB R3E 3P4, Canada
4. Department of Internal Medicine, University of Manitoba, Winnipeg, MB R3E 3P4, Canada
5. Manitoba Centre for Advanced Cell & Tissue Therapy, Winnipeg, MB R3A 1R9, Canada
Interests: autoimmune diseases; transplantation; immunotherapy; cytokines; novel cellular therapy; immune regulatory cells
Special Issue Information
Dear Colleagues,
We invite scientists to submit original research articles and literature reviews that seek to explore the development and efficacy of cell and gene therapies for the treatment of immune diseases. Potential topics include, but are not limited to, the following:
- Development/application of novel cell and gene therapies for treating cancers, including CARs, TCR-T cells, TILs and others.
- Development/application of novel gene therapies for genetic diseases.
- Development/application of novel cell and gene therapies for autoimmune diseases, infection, cardiovascular disease and other disorders.
- Gene vector design.
- Exploration of delivery routes of genes or gene-editing reagents to the relevant target cells.
Dr. Qingdong Guan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cell therapy
- gene therapy
- chimeric antigen receptor T cells
- T cell receptor-engineered T cells
- tumor-infiltrating lymphocytes
- hematopoietic stem cells
- chimeric antigen receptor NK cells
- induced pluripotent stem cells
- mesenchymal stem/stromal cells
- immune regulatory cells
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
